Abiraterone Acetate (CAS 154229-18-2)

Abiraterone Acetate Property Table ​Field ​Value ​Name 17-(3-pyridyl)-5,16-androstadien-3β-acetate ​CAS 154229-18-2 ​Synonyms ZYTIGA, CB 7630, Abiraterone Acetate, 3β-acetoxy-17-(3-pyridyl)androsta-5,16-diene, etc. ​EINECS (EC#) 620-314-7 ​Molecular Formula C₂₆H₃₃NO₂ ​Molecular Weight 391.55 ​Appearance White to beige powder ​Melting Point 127-130 °C ​Boiling Point 506.7 ± 50.0 °C (Predicted) ​Density 1.14 ± 0.1 g/cm³ (Predicted) ​Refractive Index 1.583 (Predicted) ​Storage Temp. -20°C Freezer ​Solubility Slightly soluble in chloroform; sparingly soluble in DMSO and methanol ​Form Powder ​pKa 5.31 ± 0.12 (Predicted) ​Color White to beige ​Usage Non-steroidal anti-inflammatory; inhibits CYP17 enzyme (17α-hydroxylase/C17,20-lyase), used for metastatic castration-resistant prostate cancer (mCRPC) and hormone-sensitive prostate cancer (HSPC). Requires prednisone co-administration. ​Pharmacology Selective CYP17 inhibitor; reduces testosterone levels below castration levels. ​Clinical Use – ​Indications: mCRPC, HSPC, prostate cancer bone metastasis.– ​Dosage: 1000 mg/day, fasting. ​Side Effects Common: Hypertension, hypokalemia, edema.Severe: Hepatotoxicity (monitor ALT/AST), cardiovascular events. ​Synthesis Synthesized from 3β-acetoxyandrosta-5,16-diene via palladium-catalyzed coupling. ​Regulatory Status FDA-approved (2011), EMA-approved (2011). ​Key References Clinical trials (Stein et al., 2014; Richards et al., 2012; Li et al., 2012). ​Additional Notes